Mask capable of slowly releasing medicine and medicine core bag

Abstract

The mask capable of slowly releasing the medicine comprises a mask body and mask belts connected to the mask body, the inner side of the mask body is provided with a bag body, the bag body is located at the upper middle portion of the mask, and at least one medicine core bag can be placed in the bag body; and a drug core package thereof.

Description

Technical Field

[0001] The invention belongs to the technical field of masks and relates to a mask capable of sustained-releasing drugs and a drug core package, which can relieve influenza, headache, nasal congestion, sore throat and refresh the brain. Background Art

[0002] As an important personal protective equipment, masks can effectively help people filter impurities in the air and protect our respiratory system, thereby blocking germs, bacteria and various dust particles from entering our mouths and noses, reducing the risk of respiratory diseases and infections.

[0003] The masks currently available on the market only provide basic isolation functions and do not have the effect of preventing or treating diseases. Therefore, it is particularly necessary to design a mask that can slowly release drugs to solve the above problems. Summary of the invention

[0004] In order to solve the shortcomings of the prior art, the present invention provides a mask and a drug core package that can slowly release drugs. The mask is used as a carrier, and a drug core package is arranged in the mask. Critically ill patients can embed the required number of drug core packages in the mask, which has more significant and simpler therapeutic effects.

[0005] To achieve the above-mentioned purpose, the technical solution of the present invention is: a mask capable of sustained-release of drugs, comprising a mask body and a mask strap connected to the mask body, wherein the inner side of the mask body has a bag body, the bag body is located in the middle and upper part of the mask, and at least one drug core package can be placed in the bag body.

[0006] A drug core package, the composition of which consists of the following components in percentage by weight: 1.8-6.12% of borneol, 4-12% of borneol, 0.5-2% of magnolol, 1-4% of honokiol, 0.6-2% of isomagnoliol, 1.25-4% of tetrahydromagnoliol, 4.3-18.18% of beta-eudesmol, 6.8-23.95% of euphorbia cerifera, 3.7-16.52% of 1-caryophyllene, 3.1-10.35% of patchouli alcohol, and the rest is neolignans.

[0007] The specific steps of preparing the drug core package are to screen the composition through 120-150 mesh and mix it evenly.

[0008] The weight of the composition of the drug core package is 6-10g.

[0009] By adopting the above technical solution, the beneficial effects of the present invention are:

[0010] The mask of the present invention is easy to wear, does not require medication or injection, and is suitable for men, women, old and young; at the same time, the drug core package has the functions of slowly releasing moisture in the oral cavity, nasal cavity and throat, sublimating drugs absorbed through the nasal mucosa, entering the blood to inhibit and kill bacteria and viruses. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 It is a three-dimensional structural schematic diagram of the present invention.

[0012] In the figure, 1. mask body; 2. mask strap; 3. bag body; 4. drug core package. DETAILED DESCRIPTION

[0013] In order to further explain the technical solution of the present invention, the present invention is described in detail below through specific embodiments.

[0014] like Figure 1 As shown, the mask capable of sustained-release of drugs comprises a mask body 1 and a mask strap 2 connected to the mask body 1. The inner side of the mask body 1 has a bag body 3, which is located in the middle and upper part of the mask. At least one drug core package 4 can be placed in the bag body 3.

[0015] The composition in the drug core package 4 is composed of the following ingredients in weight percentage: borneol 1.8-6.12%, borneol 4-12%, magnolol 0.5-2%, honokiol 1-4%, isomagnokiol 0.6-2%, tetrahydromagnokiol 1.25-4%, β-eudesmol 4.3-18.18%, euphorbia alcohol 6.8-23.95%, 1-caryophyllene 3.7-16.52%, patchouli alcohol 3.1-10.35%, and the rest are neolignans.

[0016] In this embodiment, the composition in the drug core package 4 is composed of the following ingredients in weight percentage: 5.2% borneol, 10% borneol, 1.7% magnolol, 3.8% honokiol, 1.8% isomagnolia officinalis, 3.5% tetrahydromagnolia officinalis, 17.1% β-eucalyptol, 22.3% eucalyptol, 14.3% 1-caryophyllene, 9.6% patchouli alcohol, and 10.7% neolignans.

[0017] The specific steps of preparing the drug core package 4 are to screen the composition through 120-150 mesh and mix it evenly.

[0018] The weight of the composition of the drug core package 4 is 6-10 g. In this embodiment, the weight of the composition of the drug core package 4 is 8 g.

[0019] The volatile components of the drug core package 4 are directly transmitted to the brain through the olfactory nerves, regulating the response of the cerebral cortex, stimulating the various central nervous systems through drugs, and quickly adjusting the functions of the internal organs to achieve the effect of curing diseases.

[0020] The drug core package 4 can refresh the mind, clear away heat and detoxify, warm the lungs and eliminate phlegm, relieve sore throat and treat wheezing, warm the kidneys and clear the body, calm the mind and calm the nerves; it can also treat headaches and toothaches.

[0021] The β-eucalyptol in the drug core has an inhibitory effect on Staphylococcus aureus, Staphylococcus epidermidis, Candida albicans, and Enterococcus faecalis.

[0022] Borneol can open the blood-brain barrier. Its main mechanism is to promote the opening of the blood-brain barrier by increasing the levels of histamine and 5-hydroxytryptamine in the hypothalamus.

[0023] The drug core package 4 has the inhibitory and inactivating effects on Streptococcus pneumoniae, Escherichia coli, Mycobacterium tuberculosis, Corynebacterium diphtheriae, and Vibrio cholerae. It also has the effects of resisting influenza virus.

[0024] The present invention is placed in the mouth and nose, and utilizes the heat exhaled from the nasal cavity to promote the volatilization of the medicine in the medicine core package 4, and inhales it into the body to achieve the purpose of treating the disease. Compared with traditional oral drugs, the present invention only requires one tenth of the dosage of traditional oral drugs while achieving the same therapeutic effect.

[0025] In practice, after the drug core package 4 is embedded in the bag body 3, it will not cause any impact on the normal wearing of the mask.

[0026] The above components are all common standard parts or components known to those skilled in the art, and their structures and principles can be known to those skilled in the art through technical manuals or conventional experimental methods.

[0027] The above embodiments and drawings do not limit the product form and style of the present invention. Any appropriate changes or modifications made by ordinary technicians in the relevant technical field should be deemed to be within the patent scope of the present invention.

Claims

1. A mask capable of sustained-release of drugs, comprising a mask body (1) and a mask strap (2) connected to the mask body (1), wherein the inner side of the mask body (1) is provided with a bag body (3), the bag body (3) being located in the middle and upper part of the mask, and at least one drug core package (4) can be placed in the bag body (3).

2. A drug core package, characterized in that: The composition is composed of the following components according to weight percentage: 1.8-6.12% of borneol, 4-12% of borneol, 0.5-2% of magnolol, 1-4% of honokiol, 0.6-2% of isomagnoliol, 1.25-4% of tetrahydromagnoliol, 4.3-18.18% of beta-eudesmol, 6.8-23.95% of euphorbia alcohol, 3.7-16.52% of 1-caryophyllene, 3.1-10.35% of patchouli alcohol, and the rest are neolignans.

3. A drug core package according to claim 2, characterized in that: The specific steps of preparing the drug core package (4) are to screen the composition through 120-150 mesh and mix it evenly.

4. A drug core package according to claim 2, characterized in that: The composition weight of the drug core package (4) is 6-10 g.

Images